Related Experiment Video
Updated: Jun 29, 2025

Tilt Testing with Combined Lower Body Negative Pressure: a "Gold Standard" for Measuring Orthostatic Tolerance
Published on: March 21, 2013
Mechanism-based therapy of non-cardiac syncope: a practical guide
Michele Brignole1, Giulia Rivasi2, Artur Fedorowski3,4
1IRCCS Istituto Auxologico Italiano, Faint and Fall Research Centre, Department of Cardiology, S. Luca Hospital, Piazzale Brescia 20, 20149 Milano, Italy.
Non-cardiac syncope management requires identifying hemodynamic mechanisms. Effective therapies target either the hypotensive or bradycardic phenotype to prevent recurrent syncope.
Area of Science:
- Cardiology
- Neurology
- Internal Medicine
Background:
- Non-cardiac syncope encompasses transient loss of consciousness excluding primary cardiac causes.
- Reflex syncope and orthostatic hypotension are common etiologies.
- Current therapeutic strategies lack universal efficacy, necessitating mechanism-based approaches.
Purpose of the Study:
- To highlight the importance of identifying hemodynamic mechanisms in non-cardiac syncope.
- To differentiate between hypotensive and bradycardic syncope phenotypes.
- To guide personalized therapy selection based on syncope phenotype.
Main Methods:
- Clinical assessment to rule out cardiac syncope.
- Hemodynamic phenotyping to distinguish between hypotensive and bradycardic mechanisms.
- Review of therapeutic interventions tailored to specific phenotypes.
Main Results:
- Non-cardiac syncope is characterized by two primary hemodynamic phenotypes: hypotensive and bradycardic.
- Therapeutic efficacy is determined by the underlying hemodynamic mechanism, not solely the etiology.
- Specific treatments are effective for each phenotype: e.g., fluid management and vasopressors for hypotension, pacing for bradycardia.
Conclusions:
- Personalized therapy for non-cardiac syncope hinges on accurate hemodynamic phenotyping.
- Targeting hypotension or bradycardia is crucial for effective syncope management.
- Differentiating syncope phenotypes allows for optimized treatment strategies and recurrence prevention.
More Related Videos
09:52Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide
Published on: January 15, 2017
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Mechanism of Cardiac Arrhythmias
Heart Failure Drugs: β-Blockers
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers